Tamura Yutaka, Monden Mayuko, Suzuki Hiroto, Yamada Masashi, Koyama Keizo, Shiomi Hirohito
Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Japan.
J Pharmacol Sci. 2006 Oct;102(2):248-52. doi: 10.1254/jphs.sc0060082. Epub 2006 Oct 12.
The effects of 2,4,4-trimethyl-3-(15-hydroxypentadecyl)-2-cyclohexen-1-one (tCFA15) on diabetic hypoalgesia and neuropathic hyperalgesia were examined. Treatments of streptozotocin (STZ)-pretreated mice with tCFA15 (8 - 40 mg/kg, i.p.) for 7 days significantly reversed the depressed inflammatory nociceptive licking response in the formalin test. In addition, similar drug treatments and dosing in 7-day postoperative neuropathic pain model rats (prepared by the method of Bennett and Xie) yielded a similarly favorable outcome by significantly reversing decreased nociceptive thresholds in the paw pressure test. These results suggest that tCFA15 may have the potential to normalize sensory nerve abnormalities induced in experimental diabetes and nerve injury.
研究了2,4,4-三甲基-3-(15-羟基十五烷基)-2-环己烯-1-酮(tCFA15)对糖尿病性痛觉减退和神经性痛觉过敏的影响。用tCFA15(8 - 40mg/kg，腹腔注射)对链脲佐菌素(STZ)预处理的小鼠进行7天治疗，可显著逆转福尔马林试验中降低的炎性伤害性舔舐反应。此外，在7天术后神经性疼痛模型大鼠(采用Bennett和Xie的方法制备)中进行类似的药物治疗和给药，通过显著逆转爪部压力试验中降低的伤害性阈值，也产生了类似的良好效果。这些结果表明，tCFA15可能具有使实验性糖尿病和神经损伤诱导的感觉神经异常恢复正常的潜力。
